Hong Kong's OrbusNeich H1 revenue rises

OrbusNeich Medical group

13/08/2026 09:42

Overview
Hong Kong medical device maker's H1 revenue rose 18% yr/yr, with growth in all regions
Profit attributable to owners increased 9% yr/yr for the interim period
Company declared interim dividend of HK8 cents per share for H1 2026

Outlook
In short term, expects to continue to achieve strong revenue growth, supported by the gradual increase in sales of eucatech AG and Scoreflex QUAD products

Result Drivers
PRODUCT LAUNCHES - Growth in APAC, Japan, and the US was driven by increased sales of new products such as Scoreflex TRIO, Scoreflex QUAD, and JADE PLUS
EXPANDED DIRECT SALES - Revenue growth in EMEA and APAC benefited from the establishment of new direct sales teams and conversion of markets to direct sales
REGULATORY APPROVALS - Additional product approvals in multiple regions contributed to sales growth

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
H1 Revenue
 
$98.70 mln
 
H1 Net Income Attributable
 
$21.60 mln
 

Analyst Coverage
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."
Wall Street's median 12-month price target for OrbusNeich Medical Group Holdings Ltd is HK$5.55, about 46.2% above its August 12 closing price of HK$3.80
The stock recently traded at 9 times the next 12-month earnings vs. a P/E of 9 three months ago

Reuters Recommended Reads
Aug 12 - Hong Kong's Qianhai Health interim revenue falls on supply constraints
Aug 13 - Germany's Ottobock H1 core revenue rises 7.7%, EBITDA margin improves
Aug 11 - Stereotaxis Q2 revenue misses estimates, dragged by system decline

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

Press Release s3://eap-prd-eu-west-1-source-content/eap_feed_proxy/fingerpost/HKSW/2026-08-13/c924a509-cb6f-4448-b8c7-11d149c6cb0b.file
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)